Rigel Pharmaceuticals (RI2) Stock Overview
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RI2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.26 |
| 52 Week High | US$43.40 |
| 52 Week Low | US$15.80 |
| Beta | 1.13 |
| 1 Month Change | 36.63% |
| 3 Month Change | 51.53% |
| 1 Year Change | 132.88% |
| 3 Year Change | 225.70% |
| 5 Year Change | 8.98% |
| Change since IPO | -53.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| RI2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.9% | -1.2% | -2.5% |
| 1Y | 132.9% | 14.7% | -0.6% |
Return vs Industry: RI2 exceeded the German Biotechs industry which returned 13.8% over the past year.
Return vs Market: RI2 exceeded the German Market which returned -0.6% over the past year.
Price Volatility
| RI2 volatility | |
|---|---|
| RI2 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: RI2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RI2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 173 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RI2 fundamental statistics | |
|---|---|
| Market cap | €689.72m |
| Earnings (TTM) | €319.10m |
| Revenue (TTM) | €262.63m |
Is RI2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RI2 income statement (TTM) | |
|---|---|
| Revenue | US$299.77m |
| Cost of Revenue | US$56.35m |
| Gross Profit | US$243.41m |
| Other Expenses | -US$120.82m |
| Earnings | US$364.23m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.69 |
| Gross Margin | 81.20% |
| Net Profit Margin | 121.51% |
| Debt/Equity Ratio | 11.2% |
How did RI2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 04:51 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rigel Pharmaceuticals, Inc. is covered by 20 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |